FDA Approves Leucovorin for Folate Deficiency, Backtracks on Autism Claims

The Food and Drug Administration (FDA) approved a drug to treat a rare brain disorder that shares some characteristics with autism, but has clarified that the medication is not a treatment for autism itself. The decision follows earlier statements from health officials suggesting the drug, leucovorin, could potentially benefit “hundreds of thousands” of children with autism. The approval specifically covers the treatment of cerebral folate deficiency (CFD), a genetic condition affecting folate transport to the brain.

Leucovorin, originally marketed as Wellcovorin by GSK before production ceased in 1997, will be available for both children and adults diagnosed with CFD. GSK does not plan to resume manufacturing or marketing Wellcovorin, meaning patients will likely access generic formulations of leucovorin. The FDA’s approval letter details the specific conditions for use and the data supporting the decision.

Understanding Cerebral Folate Deficiency

Cerebral folate deficiency is a rare genetic disorder where the brain doesn’t receive enough folate, a crucial B vitamin. This deficiency can lead to a range of neurological symptoms, including seizures, motor skill difficulties, and developmental delays. While these symptoms can overlap with those seen in autism spectrum disorder, CFD is a distinct condition with a specific underlying cause: impaired folate transport across the blood-brain barrier. It’s estimated that around 1 million Americans live with some form of this rare genetic condition.

The FDA’s shift in focus comes after a review of the evidence, prompted by concerns that initial statements had overstated the potential benefits of leucovorin for autism. Senior FDA officials told the Associated Press that the agency narrowed its review to concentrate on uses supported by more robust scientific evidence. This decision underscores the importance of rigorous scientific evaluation in drug approvals and the need to avoid premature conclusions based on limited data.

The Autism Connection and Evolving Evidence

The initial interest in leucovorin as a potential autism treatment stemmed from the observation that some individuals with autism also exhibit folate deficiencies. Folinic acid, a related compound, has shown some promise in improving symptoms in people with documented folate deficiency. However, the evidence supporting leucovorin’s efficacy in autism specifically has been mixed. A large study initially suggesting positive effects was later retracted in January due to concerns about the data.

Despite the lack of conclusive evidence, demand for leucovorin surged following a September 2025 press conference where former President Trump and other officials highlighted its potential for autism treatment. According to a study published in The Lancet, outpatient prescriptions for leucovorin rose by 71% in the weeks following the press conference, indicating a significant increase in off-label use.

What Does This Mean for Patients and Families?

The FDA’s approval provides a targeted treatment option for individuals with confirmed cerebral folate deficiency. Diagnosis typically involves genetic testing to identify mutations in the FOLR1 gene, which is responsible for folate transport. For those diagnosed with CFD, leucovorin can help improve folate levels in the brain, potentially alleviating neurological symptoms.

However, it’s crucial to understand that this approval does not extend to autism. The FDA has explicitly stated that leucovorin is not approved as a treatment for autism spectrum disorder, and there is currently insufficient evidence to support its use for this purpose. Families of children with autism should continue to rely on evidence-based therapies and interventions recommended by qualified healthcare professionals.

Distinguishing CFD from Autism: A Critical Difference

While both CFD and autism can present with developmental delays, they are fundamentally different conditions. Autism is a neurodevelopmental disorder with a complex interplay of genetic and environmental factors. CFD, is a specific metabolic disorder caused by a deficiency in folate transport. Treating autism requires a multifaceted approach tailored to the individual’s needs, while CFD requires addressing the underlying folate deficiency.

The Regulatory Process and Future Research

The FDA’s decision to approve leucovorin for CFD reflects the agency’s commitment to addressing rare diseases and repurposing existing medications for new indications. This process often involves reviewing existing data, including case reports and observational studies, to identify potential benefits. In this case, the FDA acted on data from case reports of genetically confirmed CFD identified by the agency itself. GSK is updating the label for Wellcovorin to reflect this new indication.

The FDA’s recent actions also highlight the importance of careful communication and transparency in public health messaging. The initial statements regarding leucovorin and autism generated significant hope among families, but also raised concerns about the potential for off-label use and unrealistic expectations. The agency’s subsequent clarification underscores the need to base treatment decisions on solid scientific evidence and to avoid overstating the benefits of unproven therapies.

Looking ahead, further research is needed to better understand the role of folate in brain development and function. Studies are ongoing to investigate the potential benefits of folate supplementation in individuals with autism, but these studies must be rigorously designed and carefully interpreted. The FDA will continue to monitor the safety and efficacy of leucovorin and will update its guidance as new evidence emerges.

What to expect moving forward: The FDA will likely continue to prioritize the review of applications for treatments of rare diseases, particularly those with unmet medical needs. Ongoing surveillance of leucovorin use will help to identify any potential safety concerns and to assess the long-term benefits of treatment for CFD. Families and healthcare providers should stay informed about the latest updates from the FDA and other reputable sources.